Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000151010 | SCV000198720 | likely benign | not specified | 2013-04-15 | criteria provided, single submitter | clinical testing | Pro128Pro in exon 3 of MAP2K2: This variant is not expected to have clinical si gnificance because it does not alter an amino acid residue and is not located ne ar a splice junction. |
Labcorp Genetics |
RCV001476321 | SCV001680529 | likely benign | RASopathy | 2023-03-23 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000151010 | SCV001748757 | likely benign | not specified | 2021-06-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004992021 | SCV005616840 | likely benign | Cardiovascular phenotype | 2024-10-20 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004745217 | SCV005347622 | likely benign | MAP2K2-related disorder | 2024-04-05 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |